A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation - Wikidata - awgldk - TriplyDB

A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation

A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation

http://www.wikidata.org/entity/Q35379384

about

Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View Recurrence and Treatment after Renal Transplantation in Children with FSGS Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates Update on the treatment of focal segmental glomerulosclerosis in renal transplantation FSGS Recurrence in Adults after Renal Transplantation A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues Unraveling the Role of Allo-Antibodies and Transplant Injury Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.Circulating CD40 autoantibody and suPAR synergy drives glomerular injury.Autoantibodies targeting glomerular annexin A2 identify patients with proliferative lupus nephritis.Soluble Urokinase Receptor and Chronic Kidney Disease.Drug discovery in focal and segmental glomerulosclerosis Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation Systemic and renal lipids in kidney disease development and progression.Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.Rituximab is not a "magic drug" in post-transplant recurrence of nephrotic syndrome.Recurrent focal segmental glomerulosclerosis after kidney transplantation.Regulatory T cells and minimal change nephropathy: in the midst of a complex network.CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease.Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.Unwinding focal segmental glomerulosclerosis Focal segmental glomerular sclerosis: do not overlook the role of immune response.Extrarenal determinants of kidney filter function.Immunology of idiopathic nephrotic syndrome.The importance of non-HLA antibodies in transplantation.Focal Segmental Glomerulosclerosis.Glomerular disease: new screen predicts FSGS recurrence.Transplant genetics and genomics.What are we missing in the clinical trials of focal segmental glomerulosclerosis?Optimal management of primary focal segmental glomerulosclerosis in adults Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome.PLA2R and THSD7A: Disparate Paths to the Same Disease?suPAR and chronic kidney disease-a podocyte story.Successful Treatment of Focal Segmental Glomerulosclerosis after Kidney Transplantation with Plasma Exchange and Abatacept in a Patient with Juvenile Rheumatoid Arthritis.CD40 Generation 2.5 Antisense Oligonucleotide Treatment Attenuates Doxorubicin-induced Nephropathy and Kidney Inflammation.Fatal rituximab-associated lung injury syndrome in a patient treated with rituximab for recurrence of post-transplant nephrotic syndrome.Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor.Renal and Hematological Effects of CLCF-1, a B-Cell-Stimulating Cytokine of the IL-6 Family.The anti-CD40 auto-antibody: a biomarker or a factor for the permeability of recurrent focal segmental glomerulosclerosis?

P2860

Q26738374-01292F74-0C4F-409A-A263-0A2ECE9BC477 Q26746985-5A611014-4CA6-4F3C-B195-B51D40306EBA Q26747221-9B0AB787-5A57-4C73-BCFB-C7C8937BE937 Q26751470-AA55CE48-515A-43D1-962B-2AA99439EF44 Q26752840-559DA7F9-FED7-426A-8375-BB0976B905CE Q26776389-9B40D5E0-A7FF-4265-87CB-DE045107CDF3 Q28069336-EF48DA2E-8E2B-4963-BBD9-E25D586F3EBB Q33605113-D032AA50-5E7B-4F48-8FD7-AFBC48354350 Q35704498-B3E338F2-4371-431B-BC5A-6EBD7BE006FC Q36352504-FB76D2CF-A9D3-4B5B-AD04-89CA02A2AD0B Q36403276-C71DF44D-A19D-4238-BA57-45364BE2D8D3 Q36429637-0E2D729D-8DAB-4B39-8F72-A16C21E66E2A Q36924116-230E5374-23B5-4521-9684-14B5982D04D0 Q36987307-F002EC7E-EB34-45EC-BA34-CA46A6017FB4 Q37148885-81B6F283-AB39-490E-A145-DA02FECBC790 Q37217446-ACDB6A2E-FDC7-4C92-A343-C2349968BBF9 Q37218346-0D7FDF85-C074-4E97-9060-C7DC3035D71B Q38359297-8C492A99-C021-43B7-BDFC-1C4E1B8CABA6 Q38543132-DD4DCF0B-BBB1-406D-9E6A-FC0398563EF5 Q38593433-830BC8C3-12BA-49B6-82F8-1DC4F2EA54E9 Q38679589-DEE9D66F-A757-4C77-80DA-8AD798E76EE9 Q38685434-C9FAEAC4-B615-4F0E-9559-F34693436826 Q38742004-B6CDFD9C-5DDD-49B9-A4DF-A584587AF76B Q38754939-E86A7F84-B144-4415-AF09-53C539983C51 Q38815449-BAEAFFC0-07C6-475C-A3F8-1C62ABDF6591 Q38877375-888DC25F-7483-4AD0-A331-D38AE1B57302 Q38938623-FC29B823-1D38-478F-BF50-56C00667BCC9 Q39110218-5D10935B-9E9F-4030-8C58-1E14250645C9 Q39175303-FC100145-DB3C-4AEA-9A64-D1DD726C3633 Q39229298-E43996A2-BC97-4761-B329-4A7A21212224 Q39331611-E42F546D-454F-4FCC-A6FB-B275BF9814A5 Q39335899-FADCC721-20FF-42E3-A045-E4D48F58A709 Q39412533-F04E7E0D-E732-4C51-960D-5FB064AEADAC Q39423366-5D005AE5-CC8B-4242-B1B0-A5E9B283019A Q39815667-7D98815D-6951-4D17-B363-C75F27FAF0F2 Q40256254-A8F779FB-04F5-4672-BA39-DEFCB36F15AC Q41269163-266F8E67-284D-4DCC-AAD8-960717C31CE3 Q41688065-4870DAB3-10B3-43E9-8CF7-742C547EEC2E Q42254379-D11521CB-3E8D-424B-8C14-FCF8BB86378F Q42403776-B15DCB33-9AC1-4A02-A62A-49163C7E2FA8

P2860

A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation

http://www.wikidata.org/entity/Q35379384

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A circulating antibody panel f ...... e after kidney transplantation

@ast

A circulating antibody panel f ...... e after kidney transplantation

@en

type

label

A circulating antibody panel f ...... e after kidney transplantation

@ast

A circulating antibody panel f ...... e after kidney transplantation

@en

prefLabel

A circulating antibody panel f ...... e after kidney transplantation

@ast

A circulating antibody panel f ...... e after kidney transplantation

@en

P1433

Q35379384-49A20B63-BEFA-4E17-8F66-04126EFF65FB

P1476

Q35379384-FE77927E-F36A-4F21-BC5E-FD0482301E78

P2093

Q35379384-109F87F1-9057-4E9E-84FA-883302B696B2

Q35379384-1F6FE654-34CF-4202-AADD-8ABF789BC2CA

Q35379384-1F890DA0-2273-4206-A376-F3B7DD8DB70C

Q35379384-2B8BA76A-145D-42EE-B7D4-B8277E97D8AB

Q35379384-3A00DAB4-5239-4B41-A55C-60F092D9E104

Q35379384-5E6B8359-121E-4C98-8D37-31A39017C1F8

Q35379384-742BB6BD-BA23-4AFC-8D01-C1C68523312D

Q35379384-9CEF60B1-C604-466F-AAF4-6E73EA48A9F5

Q35379384-ACFD3DB3-70A2-4834-B77A-3A69B007DFD9

Q35379384-B4A9CA2C-C1C1-4B4E-8EB6-B81BB6967FDF

P2860

Q35379384-02207AA6-3B8B-455F-B98D-652EB752FC45

Q35379384-03040E46-935F-48A6-A689-8F6DFC09C73F

Q35379384-0437B5DC-C0C8-476A-9ECF-D90AF88A5A02

Q35379384-06F65268-E175-4AC4-B097-D7D8FAAD422E

Q35379384-1ED18F9F-03D6-4543-A1DE-A1F78BA77E68

Q35379384-23A45F82-120C-48EE-90FA-D3D64883A452

Q35379384-28990416-B8D3-45A3-9DA9-2903C57D7CE5

Q35379384-30B322E2-945A-4DCF-B7CF-223C78ADCE0C

Q35379384-358C7E8E-DCF4-4026-9FA1-8DD878FE4B1A

Q35379384-3AB61810-E020-426D-BF1B-3433C3031EB2

P304

Q35379384-23B66DE8-9B7C-48FD-97EF-CF867569CE97

P31

Q35379384-8521FD01-1C83-48C8-914C-A45269C632E1

P356

Q35379384-319F933A-B9CC-4B19-9F93-98B45AE80333

P407

Q35379384-19CFE4D8-61BC-4F3D-B95E-BD851978D5AB

P433

Q35379384-A6084E30-2C25-4C56-A1B2-41B4441193A0

P478

Q35379384-268D4FE9-D0F6-4F71-BF46-F1BF4D37A3CA

P50

Q35379384-10E77150-CC2D-4A98-B3F8-CCDF3CA5105E

Q35379384-2BBD11CA-AF8A-4902-98D2-55B45944A4DA

Q35379384-E7BAF268-7B01-4966-8293-E542BD4834CC

P577

Q35379384-02F26DD7-8D04-4134-995B-83DCB7E25B5D

P5875

Q35379384-66A573D1-3226-47C1-97A1-818D28625CBF

P698

Q35379384-B115274E-FF80-413F-AC0D-2BECE05C60D3

P921

Q35379384-4477CEFF-9700-40FF-B0F5-795D2B2D30C8

P932

Q35379384-F9308485-7ED0-42A2-8FB6-3223A2DA3C5E

P356

SCITRANSLMED.3008538

P1433

Science Translational Medicine

P1476

A circulating antibody panel f ...... e after kidney transplantation

@en

P2093

Alessia Fornoni

http://www.w3.org/2001/XMLSchema#string

Annette Jackson

http://www.w3.org/2001/XMLSchema#string

Changli Wei

http://www.w3.org/2001/XMLSchema#string

Christophe Legendre

http://www.w3.org/2001/XMLSchema#string

Dany Anglicheau

http://www.w3.org/2001/XMLSchema#string

George W Burke

http://www.w3.org/2001/XMLSchema#string

Guillaume Canaud

http://www.w3.org/2001/XMLSchema#string

Jing Li

http://www.w3.org/2001/XMLSchema#string

Jochen Reiser

http://www.w3.org/2001/XMLSchema#string

Minnie M Sarwal

http://www.w3.org/2001/XMLSchema#string

P2860

Protein microarrays discover angiotensinogen and PRKRIP1 as novel targets for autoantibodies in chronic renal disease

Truncation of C-mip (Tc-mip), a new proximal signaling protein, induces c-maf Th2 transcription factor and cytoskeleton reorganization

Antibodies to protein tyrosine phosphatase receptor type O (PTPro) increase glomerular albumin permeability (P(alb))

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.

Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus.

Circulating anti-actin and anti-ATP synthase antibodies identify a sub-set of patients with idiopathic nephrotic syndrome.

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.

Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy

suPAR and Team Nephrology

Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis

P304

256ra136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3008538

http://www.w3.org/2001/XMLSchema#string

P407

P433

256

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Maarten Naesens

Marianne Delville

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267756446

http://www.w3.org/2001/XMLSchema#string

P698

25273097

http://www.w3.org/2001/XMLSchema#string

P921

P932

4394366

http://www.w3.org/2001/XMLSchema#string